Furthermore, MCC950 rescued neonatal lethality in a mouse model of CAPS, and it was effective in reducing IL-1β levels in human peripheral blood mononuclear cells from patients with Muckle–Wells syndrome, thus suggesting its putative therapeutic activity in NLRP3-associated syndromes, including autoinflammatory and autoimmune diseases (72). Here, IL1B is linked to cryopyrin-associated periodic syndrome.